Trials / Unknown
UnknownNCT04322344
Escin in Patients With Covid-19 Infection
Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- University of Catanzaro · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In December 2019,a new type of pneumonia caused by the coronavirus (COVID-2019) broke out in Wuhan ,China, and spreads quickly to other Chinese cities and 28 countries. More than 70000 people were infected and over 2000 people died all over the world. There is no specific drug treatment for this disease. Considering that lung damage is related to both viral infection and burst of cytokines, our idea is to evaluate the efficacy and safety of escin as add-on treatment to conventional antiviral drugs in COVID-19 infected patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Escin | treatment with escin or escinate sodium |
| DRUG | standard therapy | antiviral drugs |
Timeline
- Start date
- 2020-03-23
- Primary completion
- 2020-06-30
- Completion
- 2020-12-30
- First posted
- 2020-03-26
- Last updated
- 2020-09-16
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT04322344. Inclusion in this directory is not an endorsement.